How does today's market reaction make sense?
The most immediate competiture fails and SGEN sells off in simphathy?
Does that not mean that the proven non toxic SGEN technolgy is now more valuable?
Unlike IMGN with Kadcycla, SGEN own all of ADCETRIS and none of the ~ 20 ongoing trials has shown signs of toxicity in excess with what is standard for oncology drugs.
Your questions seem rhetorical and may, at least for some, further support their long term investment thesis in SGEN as a, presently, "best in class" ADC pharma.
I think that some of the issues which have been noted with the basic IMGN linker system ( apparently ) highlight the fact that ADC technology and production is a complex process involving many exquisitely sensitive variables. It also may serve to remind us that it might, thus, be harder more than easier to produce generics or "bio-similars" that can precisely achieve the full efficacy and safety of the original well honed and time tested product.